Prosecution Insights
Last updated: August 09, 2026

Huabo Biopharm (Shanghai) Co. Ltd.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
1
Medium (33%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (33%)
Double-patenting + other1 (33%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BUNNER, BRIDGET E 1 64.4% +20.1%
DONOGHUE, BRITTNEY ERIN 1 58.6% +48.8%
HINES, JANA A 1 52.9% +39.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18039733 ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF DONOGHUE, BRITTNEY ERIN

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18265529 CD73 ANTIGEN-BINDING PROTEIN AND APPLICATION THEREOF BUNNER, BRIDGET E
18039733 ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF DONOGHUE, BRITTNEY ERIN
18034985 ANTIBODY TARGETING INTERLEUKIN 36R, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF HINES, JANA A

Top Art Units

Art UnitApps
1647 1
1675 1
1645 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18265529 CD73 ANTIGEN-BINDING PROTEIN AND APPLICATION THEREOF BUNNER, BRIDGET E 1647 §112DPOther Non-Final OA Pending Jun 06, 2023
18039733 ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF DONOGHUE, BRITTNEY ERIN 1675 §102§103§112 Non-Final OA Pending Jun 01, 2023
18034985 ANTIBODY TARGETING INTERLEUKIN 36R, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF HINES, JANA A 1645 §112 Non-Final OA Pending May 02, 2023

Managing Huabo Biopharm (Shanghai) Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month